Ινστιτούτο Φαρμακευτικής Έρευνας & Τεχνολογίας ΜΑΕ
IFET
The Institute of Pharmaceutical Research and Technology (IFET) is a public company of the National Pharmaceutical Organization (EOF), which was founded in 1991.
ID: 605482152677-67
Lobbying Activity
Response to Critical Medicines Act
27 Feb 2025
Please find attached the contribution of Institute of Pharmaceutical Research & Technology (IFET SA) - Supply chain challenges. EU-Level Coordination: Enhancing coordination at the EU level to effectively tackle supply chain challenges. This includes harmonizing regulations and fostering collaboration among Member States to ensure a unified approach to critical medicine supply. - Structural Vulnerabilities: Regulatory Barriers and Fragmentation: Complex and varied regulatory requirements across Member States, leading to delays and inefficiencies in the supply chain. Harmonization of regulatory requirements across Member States Reduce complexity and expedite the availability of critical medicines. Enhancing EU Manufacturing Capacities: Invest in local production through funding and collaboration between countries with strong pharmaceutical industry and others in EU. Invest in RnD for reduced and sustainable production of critical medicines Whenever possible establish publicly controlled production sites including facilities for both finished products and APIs to boost self-sufficiency. -Diversification of Supply Sources: Reduce dependency on single suppliers or regions by establishing multiple sourcing strategies and fostering international partnerships i.e., EU and USA & Canada. Do not solely rely on the lowest price, incorporate sustainability criteria - Economic and Commercial Pressures: European Solidarity Stock System in combination with exportation limits for critical medicines Implement dynamic pricing mechanisms for critical medicines (finished products and APIs). Harmonization of pricing across Member states for critical medicines. The Institute of Pharmaceutical Research and Technology (IFET S.A.), a subsidiary of the National Organization for Medicines (EOF), plays a pivotal role in ensuring the availability of critical medicines in Greece. Through the import, production, and distribution of pharmaceutical products that are otherwise unavailable in the market, IFET safeguards patient access to essential treatments and contributes significantly to public health. Our expertise extends across three key pillars: supply chain management, pharmaceutical production, and cutting-edge research. We specialize in the procurement of orphan drugs for rare diseases, the manufacturing of essential formulationsincluding methadone solutions and critical orphan medicinesand the advancement of pharmaceutical research through pre-clinical and clinical studies. Our operations are guided by a steadfast commitment to patient needs, affordability, and compliance with international standards. A crucial part of our mission is addressing medicine shortages, a challenge we tackle with a comprehensive and multidimensional approach. By integrating supply chain logistics, domestic pharmaceutical production, and dedicated research initiatives, IFET has established itself as a leading model for effectively managing shortages. This unique framework enables us to respond rapidly and efficiently, ensuring that no patient is left without vital medication. We strongly advocate for the adoption of a holistic European model based on the triad of supply chain, production, and research. Addressing shortages requires a systemic and coordinated responsefocusing on just one of these aspects will not provide a sustainable solution. IFET's unique model demonstrates that an integrated strategy is essential for securing Europe's pharmaceutical resilience, and we urge the EU to establish a similar framework at the central level.
Read full response